Matthew Shields

CIK: 0002025621

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (44.4%)

Position reduction

Option Exercises (M)3 (33.3%)

Derivative conversions

Awards (A)2 (22.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 18, 2026
Sale(S)
Direct
10K shares at avg. $32.19$322K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 3, 2026
Sale(S)
Direct
16.2K shares at avg. $32.87$532K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 3, 2026
Exercise(M)
Direct
16.2K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 5, 2026
Exercise(M)
Direct
17.3K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 5, 2026
Sale(S)
Direct
17.3K shares at avg. $31.67$548K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 4, 2026
Award(A)
Restricted Share Units
Direct
33.4K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 3, 2025
Sale(S)
Direct
6.2K shares at avg. $17.02$106K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 3, 2025
Exercise(M)
Direct
16.2K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 5, 2025
Award(A)
Restricted Share Units
Direct
69.2K shares-

		Type	Shares	Price		Ownership
Jun 18, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	9,989	$32.19	$321,547	Direct
Jun 3, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	16,195	$32.87	$532,330	Direct
Jun 3, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	16,195	-	$0	Direct
Mar 5, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	17,295	-	$0	Direct
Mar 5, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	17,295	$31.67	$547,705	Direct
Mar 4, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	33,424	-	-	Direct
Jun 3, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	6,206	$17.02	$105,628	Direct
Jun 3, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	16,195	-	-	Direct
Mar 5, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	69,182	-	-	Direct

1-9 of 9 transactions

About Shields Matthew

Shields Matthew (SEC CIK 0002025621) files insider reports with the SEC as EVP, Global Operations of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).

Signal8 holds 6 ownership filings by Shields Matthew, all Form 4s, filed between Mar 7, 2025 and Jun 22, 2026. Those filings report 9 transactions, from Mar 5, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shields Matthew's filings is in TEL AVIV.

Recent filings by Shields Matthew

Jun 18, 2026: Open-market sale of TEVA shares (Form 4, code S).
Jun 3, 2026: Open-market sale of TEVA shares (Form 4, code S).
Jun 3, 2026: Option exercise of TEVA shares (Form 4, code M).
Mar 5, 2026: Option exercise of TEVA shares (Form 4, code M).
Mar 5, 2026: Open-market sale of TEVA shares (Form 4, code S).

Other insiders filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Bergwerk Dov, Interim Cheif Legal Officer
Savage Brian, Interim Chief Legal Officer
MIGNONE ROBERTO, Director
Weiss Amir, Chief Accounting Officer
Satchi-Fainaro Ronit, Director
Lippman Evan, EVP, Business Development

How to read Form 4 transaction codes